# Phase II Pilot Study of Visudyne® Photodynamic Therapy (PDT) (Low and Very Low Fluence) Combined With Bevacizumab.

> **NCT00359164** · PHASE2 · COMPLETED · sponsor: **University of British Columbia** · enrollment: 36 (estimated)

## Conditions studied

- Macular Degeneration

## Interventions

- **DRUG:** Verteporfin Photodynamic Therapy (Low Fluence) and bevacizumab
- **DRUG:** Verteporfin Photodynamic Therapy (Very Low Fluence) and bevacizumab
- **DRUG:** Verteporfin Photodynamic Therapy (SHAM) and bevacizumab

## Key facts

- **NCT ID:** NCT00359164
- **Lead sponsor:** University of British Columbia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07
- **Primary completion:** 2008-06
- **Final completion:** 2008-08
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2008-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00359164

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00359164, "Phase II Pilot Study of Visudyne® Photodynamic Therapy (PDT) (Low and Very Low Fluence) Combined With Bevacizumab.". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT00359164. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*